This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sucampo Announces Presentation Of Results On Lubiprostone In Pediatric Functional Constipation At NASPGHAN 2013

BETHESDA, Md., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of results from a Phase 3, open-label safety and efficacy study of lubiprostone in patients with pediatric functional constipation. These results demonstrate that lubiprostone increased spontaneous bowel movement (SBM) frequency and was well-tolerated in subgroups of children and adolescents with functional constipation. These results will be presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting in Chicago, Illinois on October 11, 2013.

Lubiprostone is the world's first chloride channel activator that increases intestinal fluid secretion, softens stools and increases intraluminal fluid volume to initiate colonic transit and improve bowel function independent of motility, thereby alleviating symptoms associated with chronic constipation. The completed open-label, multicenter study evaluated both safety and efficacy in a total of 124 children and adolescents (ranging from 3 years through 17 years of age) with functional constipation who were dosed with lubiprostone 12 mcg once daily (QD), 12 mcg twice daily (BID), or 24 mcg BID.

"Pediatric functional constipation accounts for 3-5% of pediatric outpatient visits 1 and there is a definite need for new treatment options," said Paul Hyman, MD, lead author, Professor of Pediatrics at Louisiana State University and Chief, Gastroenterology at Children's Hospital. "The positive response reported by children and adolescents in this study shows that lubiprostone may represent a promising option for treating the broad range of patients who suffer from pediatric constipation."

In the fourth quarter of this year, Sucampo plans to initiate a series of global, multicenter Phase 3 studies to evaluate the efficacy, safety, and pharmacokinetics of lubiprostone in patients aged ≥ 6 months through 17 years of age with pediatric functional constipation. This program will consist of two randomized, placebo-controlled, double-blinded studies and two long-term safety extension studies.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs